AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2749352 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 15
Study 2749352 — intervention group
Group type: COMPARATOR
Intervention: Repeat electrodiagnostic testing
Number of subjects: 15
Study 6268475 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (21 g/day in three divided doses at main meals)
Number of subjects: 11
Study 6268475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30476543 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker CRT Score of 0
Number of subjects: 758
Study 30476543 — intervention group
Group type: COMPARATOR
Intervention: Composite of clinical variables
Number of subjects: 758
Study 27560946 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP0911 (fixed-dose combination of clopidogrel and aspirin)
Number of subjects: 30
Study 27560946 — intervention group
Group type: COMPARATOR
Intervention: Separate treatment with daily 75 mg clopidogrel plus 100 mg aspirin
Number of subjects: 30
Study 26152318 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 31
Study 22617861 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) at a target dose of 1.2 mg/kg per day
Number of subjects: 125
Study 22617861 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 125
Study 23327971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF: 1,974 kcal, 34% carbohydrate, 56% fat)
Number of subjects: 6
Study 23327971 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON: 1,224 kcal, 55% carbohydrate, 30% fat)
Number of subjects: 6
Study 23327971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 6
Study 23327971 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 6
Study 20053533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL)
Number of subjects: 878
Study 19463294 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 51
Study 19463294 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 51
Study 15825240 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized motor-skill analyzer for the lower limb
Number of subjects: 0
Study 12440843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthroposophical herbal remedy (20 drops 4 times daily for 4 weeks)
Number of subjects: 99
Study 12440843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 10368042 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 150 U/kg per week i.v.
Number of subjects: 50
Study 10368042 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 300 U/kg per week i.v.
Number of subjects: 50
Study 10368042 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 150 U/kg per week s.c.
Number of subjects: 50
Study 7575310 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 64
Study 7575310 — intervention group
Group type: COMPARATOR
Intervention: dummy-point acupressure
Number of subjects: 64
Study 7575310 — intervention group
Group type: COMPARATOR
Intervention: sham acupressure
Number of subjects: 64
Study 2373128 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 3770 (30 mg)
Number of subjects: 6
Study 2373128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7100036 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (4 different types prescribed for one week each over 4 weeks)
Number of subjects: 36
Study 7100036 — intervention group
Group type: COMPARATOR
Intervention: Retrospective NSAID prescribing in 164 patients
Number of subjects: 36
Study 31549178 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to prasugrel (Switched Group; n=12)
Number of subjects: 96
Study 31549178 — intervention group
Group type: COMPARATOR
Intervention: Continuing to receive clopidogrel (Continued Group; n=11)
Number of subjects: 96
Study 31162941 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ankle instability (CAI) group
Number of subjects: 100
Study 31162941 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without CAI)
Number of subjects: 100
Study 28993052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously every 2 weeks)
Number of subjects: 493
Study 28993052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 26472097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microneedling radiofrequency (FMR)
Number of subjects: 20
Study 26472097 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BR)
Number of subjects: 20
Study 23864788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PR)
Number of subjects: 48
Study 23864788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus Isosorbide-5-mononitrate (PR plus ISMN)
Number of subjects: 48
Study 22551440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin-based chemotherapy with or without docetaxel
Number of subjects: 520
Study 19145228 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeted with neuro-navigation (n=24)
Number of subjects: 51
Study 19145228 — intervention group
Group type: COMPARATOR
Intervention: rTMS applied using standard localization technique (n=27)
Number of subjects: 51
Study 17191248 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D radial pulse sequence with TE of 0.2 ms
Number of subjects: 23
Study 15135879 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating music
Number of subjects: 21
Study 15135879 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy persons)
Number of subjects: 21
Study 11519934 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of secure base representations
Number of subjects: 0
Study 11519934 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of positively valued, attachment-unrelated representations
Number of subjects: 0
Study 9678794 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 6 microg/kg/12 h
Number of subjects: 48
Study 9678794 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 8 microg/kg/12 h
Number of subjects: 48
Study 8141451 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway ventilation at pressures of 15, 20, 25, and 30 cmH2O
Number of subjects: 48
Study 8141451 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube ventilation at pressures of 15, 20, 25, and 30 cmH2O
Number of subjects: 48
Study 8141451 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway ventilation
Number of subjects: 48
Study 8141451 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube ventilation
Number of subjects: 48
Study 3046513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol driven by oxygen
Number of subjects: 27
Study 3046513 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol driven by compressed air
Number of subjects: 27
Study 30279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary DKK3-to-creatinine level >4000 pg/mg
Number of subjects: 0
Study 30279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary DKK3
Number of subjects: 0
Study 30279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in urinary DKK3 in patients with IgA nephropathy
Number of subjects: 0
Study 30279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable or decreasing urinary DKK3 in patients with IgA nephropathy
Number of subjects: 0
Study 30279273 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary DKK3 levels
Number of subjects: 0
Study 28709700 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg
Number of subjects: 45
Study 28709700 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75mg
Number of subjects: 45
Study 28709700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 45
Study 26580997 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg loading dose followed by 500 mg maintenance doses)
Number of subjects: 62
Study 26580997 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-008176 (750 mg loading dose followed by 150 mg maintenance doses)
Number of subjects: 62
Study 26580997 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-008176 (10 doses of 375 mg)
Number of subjects: 62
Study 26580997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26580997 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-008176 (all groups)
Number of subjects: 62
Study 26580997 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-008176 (all groups with loading dose)
Number of subjects: 62
Study 22924451 — intervention group
Group type: EXPERIMENTAL
Intervention: CO‐informed + BA (n = 80)
Number of subjects: 164
Study 22924451 — intervention group
Group type: COMPARATOR
Intervention: BA only (n = 84)
Number of subjects: 164
Study 22924451 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 506)
Number of subjects: 164
Study 20622695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipostabil (0.5 ml injected in one eyelid)
Number of subjects: 45
Study 20622695 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.5 ml injected in the opposite eyelid)
Number of subjects: 45
Study 18461520 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylates (sulphasalazine 2 g/d)
Number of subjects: 0
Study 18461520 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 0
Study 18461520 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 18461520 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 0
Study 18461520 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition at home
Number of subjects: 0
Study 15833934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene
Number of subjects: 1429
Study 15833934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene in women
Number of subjects: 1429
Study 15833934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentanucleotide insertion allele of the OB‐R gene in men
Number of subjects: 1429
Study 15833934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1429
Study 12053846 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography for normal foot parameters
Number of subjects: 90
Study 12053846 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography for foot stress fractures
Number of subjects: 90
Study 12053846 — intervention group
Group type: COMPARATOR
Intervention: Thermography for trainees without complaints
Number of subjects: 90
Study 12053846 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 90
Study 10595624 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg per day)
Number of subjects: 19
Study 10595624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8919898 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg eltanolone
Number of subjects: 40
Study 8919898 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg eltanolone
Number of subjects: 40
Study 8919898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg eltanolone
Number of subjects: 40
Study 8919898 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg thiopentone
Number of subjects: 40
Study 1812137 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (50 mg/kg of body weight)
Number of subjects: 8
Study 1812137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6305758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticotropin (120 U/day)
Number of subjects: 66
Study 6305758 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (300 mg/day)
Number of subjects: 66
Study 30658605 — intervention group
Group type: COMPARATOR
Intervention: IV infusion of 10 IU oxytocin
Number of subjects: 4913
Study 30658605 — intervention group
Group type: COMPARATOR
Intervention: IV bolus of 10 IU oxytocin
Number of subjects: 4913
Study 30658605 — intervention group
Group type: EXPERIMENTAL
Intervention: IM injection of 10 IU oxytocin
Number of subjects: 4913
Study 29746169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 86
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg twice-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg twice-daily)
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 330
Study 26672898 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 330
Study 24447606 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted and diffusion-weighted MRI
Number of subjects: 199
Study 22549097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible levodopa/carbidopa microtablets (LC-5), 5/1.25 mg
Number of subjects: 19
Study 22549097 — intervention group
Group type: COMPARATOR
Intervention: Standard levodopa/carbidopa (LC-100), 100/25 mg
Number of subjects: 19
Study 22549097 — intervention group
Group type: COMPARATOR
Intervention: Dispersible levodopa/benserazide (LB-100), 100/25 mg
Number of subjects: 19
Study 22549097 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (from all formulations)
Number of subjects: 19
Study 22549097 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-O-MD (from all formulations)
Number of subjects: 19
Study 19890258 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 628
Study 19890258 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 628
Study 16770448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic neck pain attributing their pain to a motor vehicle accident.
Number of subjects: 419
Study 16770448 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with chronic neck pain.
Number of subjects: 419
Study 16770448 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with chronic neck pain.
Number of subjects: 419
Study 16770448 — intervention group
Group type: COMPARATOR
Intervention: Comparison of chronic neck pain patients to chronic back pain controls.
Number of subjects: 419
Study 14570663 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil
Number of subjects: 40
Study 14570663 — intervention group
Group type: COMPARATOR
Intervention: IV sufentanil
Number of subjects: 40
Study 10761164 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent acetaminophen 1000 mg
Number of subjects: 242
Study 10761164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet acetaminophen 1000 mg
Number of subjects: 242
Study 10761164 — intervention group
Group type: COMPARATOR
Intervention: Both acetaminophen formulations
Number of subjects: 242
Study 9204788 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acetaminophen (15 mg/kg oral)
Number of subjects: 28
Study 9204788 — intervention group
Group type: COMPARATOR
Intervention: Postoperative acetaminophen (20 mg/kg rectal)
Number of subjects: 28
Study 9204788 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 1407888 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic rings
Number of subjects: 102
Study 1407888 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 102
Study 3907639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Tebonin)
Number of subjects: 8
Study 3907639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31023524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (625 mg/m2 twice per day) with cyclophosphamide (50 mg/d)
Number of subjects: 23
Study 31023524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine with cyclophosphamide
Number of subjects: 23
Study 31023524 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR baseline < 3 versus ≥ 3
Number of subjects: 23
Study 28884342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative guided imagery (GIM)
Number of subjects: 38
Study 28884342 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 38
Study 28884342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GIM and control)
Number of subjects: 38
Study 26270199 — intervention group
Group type: EXPERIMENTAL
Intervention: HeProCalc program for heparin and protamine dosing
Number of subjects: 40
Study 26270199 — intervention group
Group type: COMPARATOR
Intervention: Traditional heparin and protamine dosing based on body weight
Number of subjects: 40
Study 24618345 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Number of subjects: 767
Study 24618345 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy excluding spinal manipulation
Number of subjects: 767
Study 24618345 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy excluding stretching
Number of subjects: 767
Study 24618345 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (all groups)
Number of subjects: 767
Study 24618345 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 767
Study 21941223 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of mean arterial pressure (MAP) above 60 mmHg during surgery
Number of subjects: 32
Study 21941223 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of critical MAP value
Number of subjects: 32
Study 20571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg IV before anesthesia)
Number of subjects: 153
Study 20571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketolgan (30 mg IV before anesthesia)
Number of subjects: 153
Study 20571294 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 153
Study 20571294 — intervention group
Group type: EXPERIMENTAL
Intervention: History of migraine
Number of subjects: 153
Study 20571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-free patients
Number of subjects: 153
Study 20571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids for analgesia
Number of subjects: 153
Study 18727886 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 112
Study 18727886 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 112
Study 18727886 — intervention group
Group type: COMPARATOR
Intervention: Accuhaler
Number of subjects: 112
Study 15961941 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI)
Number of subjects: 37
Study 15961941 — intervention group
Group type: COMPARATOR
Intervention: High-strength traditional glass ionomer cement (GIC)
Number of subjects: 37
Study 12170215 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia (defined as >95th percentile in healthy individuals)
Number of subjects: 449
Study 12170215 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with patent grafts)
Number of subjects: 449
Study 10519604 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 41
Study 10519604 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 1.0%
Number of subjects: 41
Study 8719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion scintigraphy in combination with ventilation studies
Number of subjects: 25
Study 8719981 — intervention group
Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 25
Study 1787024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 240
Study 1787024 — intervention group
Group type: COMPARATOR
Intervention: 45-day detoxification
Number of subjects: 240
Study 6112324 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing oxygen
Number of subjects: 0
Study 6112324 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing oxygen for five or fifteen minutes before exercise (predose)
Number of subjects: 0
Study 6112324 — intervention group
Group type: COMPARATOR
Intervention: Breathing oxygen during exercise
Number of subjects: 0
Study 6112324 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable oxygen
Number of subjects: 0
Study 6112324 — intervention group
Group type: COMPARATOR
Intervention: Standardised progressive exercise test on a treadmill
Number of subjects: 0
Study 6112324 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise with oxygen
Number of subjects: 0
Study 30935375 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of nonavalent HPV vaccine (GARDASIL 9)
Number of subjects: 0
Study 28099472 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Tape (ET)
Number of subjects: 13
Study 28099472 — intervention group
Group type: COMPARATOR
Intervention: Sham Tape (ST)
Number of subjects: 13
Study 25844831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 138
Study 25844831 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 138
Study 25844831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and rumination group
Number of subjects: 138
Study 25844831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and rumination condition
Number of subjects: 138
Study 25844831 — intervention group
Group type: COMPARATOR
Intervention: Placebo and uninstructed condition
Number of subjects: 138
Study 24150660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination acetaminophen (48 mg·kg(‐1)·day(‐1)) and ibuprofen (24 mg·kg(‐1)·day(‐1))
Number of subjects: 152